MA55025A - Anticorps anti-trem2 et leurs procédés d'utilisation - Google Patents
Anticorps anti-trem2 et leurs procédés d'utilisationInfo
- Publication number
- MA55025A MA55025A MA055025A MA55025A MA55025A MA 55025 A MA55025 A MA 55025A MA 055025 A MA055025 A MA 055025A MA 55025 A MA55025 A MA 55025A MA 55025 A MA55025 A MA 55025A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- trem2 antibodies
- trem2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808141P | 2019-02-20 | 2019-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55025A true MA55025A (fr) | 2021-12-29 |
Family
ID=69844940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055025A MA55025A (fr) | 2019-02-20 | 2020-02-20 | Anticorps anti-trem2 et leurs procédés d'utilisation |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12240902B2 (fr) |
| EP (1) | EP3927743A1 (fr) |
| JP (2) | JP7543290B2 (fr) |
| KR (1) | KR20210135518A (fr) |
| CN (1) | CN113614110B (fr) |
| AR (1) | AR118144A1 (fr) |
| AU (1) | AU2020226754A1 (fr) |
| BR (1) | BR112021015656A2 (fr) |
| CA (1) | CA3130086A1 (fr) |
| CL (1) | CL2021002206A1 (fr) |
| CO (1) | CO2021012230A2 (fr) |
| EA (1) | EA202192294A1 (fr) |
| EC (1) | ECSP21069105A (fr) |
| IL (1) | IL285651A (fr) |
| MA (1) | MA55025A (fr) |
| MX (1) | MX2021009722A (fr) |
| PE (1) | PE20211979A1 (fr) |
| PH (1) | PH12021552002A1 (fr) |
| SG (1) | SG11202108734VA (fr) |
| TW (1) | TWI879756B (fr) |
| WO (2) | WO2020172450A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| EP3902836B1 (fr) * | 2018-12-18 | 2026-03-25 | Boehringer Ingelheim IO Canada Inc. | Anticorps agonistes de flt3 et utilisations associées |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| WO2021146256A1 (fr) * | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anticorps anti-trem2 et leurs procédés d'utilisation |
| EP4232087A4 (fr) * | 2020-10-21 | 2024-10-09 | Immune-ONC Therapeutics, Inc. | Nouveaux anticorps anti-lilrb2 et produits dérivés |
| WO2022241082A1 (fr) * | 2021-05-14 | 2022-11-17 | Genentech, Inc. | Agonistes de trem2 |
| MX2024010324A (es) | 2022-02-23 | 2024-08-30 | Alector Llc | Metodos de uso de anticuerpos anti-trem2. |
| EP4499693A1 (fr) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Molécules de liaison anti-trem2 monovalentes et leurs procédés d'utilisation |
| EP4499695A1 (fr) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Méthodes de traitement de l'hypométabolisme du glucose cérébral |
| JP2026505005A (ja) | 2023-01-30 | 2026-02-10 | イーエスアーエル バイオサイエンス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 神経変性障害を治療するためのヒト抗ｔｒｅｍ２抗体 |
| AU2024320793A1 (en) | 2023-08-09 | 2026-03-12 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| AU2024323186A1 (en) | 2023-08-09 | 2026-01-15 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025046298A2 (fr) | 2023-09-01 | 2025-03-06 | iTeos Belgium SA | Anticorps anti-trem2 et procédés d'utilisation |
| KR20260113065A (ko) * | 2023-11-15 | 2026-07-21 | 머크 샤프 앤드 돔 엘엘씨 | 인간 넥틴-4 결합제 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| RU2011133071A (ru) | 2009-01-06 | 2013-02-20 | Нестек С.А. | Переработка макронутриентов |
| NZ594514A (en) | 2009-03-05 | 2013-06-28 | Abbott Lab | Interleukin-17 BINDING PROTEINS |
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| WO2012176779A1 (fr) * | 2011-06-20 | 2012-12-27 | 協和発酵キリン株式会社 | Anticorps anti-erbb3 |
| CA2909952C (fr) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anticorps anti-cd38 et fusions sur un interferon alpha-2b attenue |
| EP3041865A2 (fr) | 2013-09-03 | 2016-07-13 | NovImmune S.A. | Molécules de liaison bispécifiques facilement isolées au format natif, mais possédant des régions constantes mutées |
| CN105218669A (zh) | 2014-06-10 | 2016-01-06 | 河北翰林生物科技有限公司 | 制备抗人r47h-trem2突变体的人单克隆抗体的方法 |
| EA201790342A1 (ru) * | 2014-08-08 | 2017-07-31 | ЭЛЕКТОР ЭлЭлСи | Антитела к trem2 и способы их применения |
| KR20240056629A (ko) | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| JP6996979B2 (ja) * | 2015-03-31 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 三量体ｔｎｆファミリーリガンドを含む抗原結合分子 |
| WO2017058866A1 (fr) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anticorps anti-trem2 et leurs utilisations |
| JP7725185B2 (ja) * | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| WO2017147509A1 (fr) | 2016-02-25 | 2017-08-31 | Marco Colonna | Compositions comprenant de la trem2 et leurs procédés d'utilisation |
| EP3448874A4 (fr) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
| JP2019531332A (ja) | 2016-07-22 | 2019-10-31 | ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー．ファウ．（デーツェットエンエー） | Ｔｒｅｍ２切断モジュレーター及びその使用 |
| CN118271442A (zh) | 2016-12-23 | 2024-07-02 | 蓝鳍生物医药公司 | 抗sez6l2抗体和抗体药物缀合物 |
| US20190367623A1 (en) | 2017-01-17 | 2019-12-05 | Yeda Research And Development Co. Ltd. | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| CA3053379A1 (fr) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anticorps anti-tau et leurs procedes d'utilisation |
| CA3053381A1 (fr) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Polypeptides modifies |
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| BR112020001060A2 (pt) | 2017-07-27 | 2020-07-14 | Novartis Ag | variantes de trem2 resistentes a shedase |
| HUE062436T2 (hu) * | 2017-08-03 | 2023-11-28 | Alector Llc | Anti-trem2 antitestek és alkalmazási módszereik |
| WO2019032955A1 (fr) | 2017-08-10 | 2019-02-14 | Denali Therapeutics Inc. | Polypeptides de liaison au récepteur de transferrine modifiés |
| WO2019055841A1 (fr) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | Anticorps anti-trem2 et leurs procédés d'utilisation |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| WO2019079529A1 (fr) | 2017-10-17 | 2019-04-25 | The Translational Genomics Research Institute | Agonistes de trem2 pour la stimulation de la microglie et des méthodes d'identification |
| WO2019094608A1 (fr) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anticorps anti-bace1 et leurs procédés d'utilisation |
| MX2020006213A (es) | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| BR112020013921A2 (pt) | 2018-01-10 | 2020-12-01 | Denali Therapeutics Inc. | polipeptídeos de ligação ao receptor de transferrina e usos destes |
| WO2019246071A1 (fr) | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Protéines de fusion comprenant de la progranuline |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| CA3109763A1 (fr) | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Proteines bispecifiques modifiees |
| EP3840781A1 (fr) | 2018-08-22 | 2021-06-30 | Denali Therapeutics Inc. | Polypeptides anti-her2 et leurs méthodes d'utilisation |
| SG11202102162RA (en) | 2018-09-11 | 2021-04-29 | Univ Washington | Anti-trem-2 agonist antibodies |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| KR102156165B1 (ko) | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| CN113302206A (zh) | 2018-11-26 | 2021-08-24 | 戴纳立制药公司 | 治疗脂质代谢失调的方法 |
| EP3894864A2 (fr) | 2018-12-10 | 2021-10-20 | Denali Therapeutics Inc. | Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation |
| CA3122725A1 (fr) | 2018-12-10 | 2020-06-18 | Mor Research Applications | Anticorps trem2 et leurs utilisations |
| CA3120875A1 (fr) | 2018-12-11 | 2020-06-18 | Pionyr Immunotherapeutics, Inc. | Methodes d'utilisation d'anticorps anti-trem2 |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| WO2020194317A1 (fr) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Méthode de traitement de troubles liés aux lipides |
| AU2020252554B2 (en) | 2019-04-03 | 2026-05-28 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
| BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| WO2021146256A1 (fr) | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anticorps anti-trem2 et leurs procédés d'utilisation |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| WO2021158986A1 (fr) | 2020-02-07 | 2021-08-12 | Denali Therapeutics Inc. | Procédés de traitement de la maladie de hunter |
| CA3170338A1 (fr) | 2020-02-19 | 2021-08-26 | Denali Therapeutics Inc. | Proteines bispecifiques anti-her2 modifiees |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
-
2020
- 2020-02-20 JP JP2021548668A patent/JP7543290B2/ja active Active
- 2020-02-20 CA CA3130086A patent/CA3130086A1/fr active Pending
- 2020-02-20 AU AU2020226754A patent/AU2020226754A1/en active Pending
- 2020-02-20 MA MA055025A patent/MA55025A/fr unknown
- 2020-02-20 WO PCT/US2020/019093 patent/WO2020172450A1/fr not_active Ceased
- 2020-02-20 WO PCT/US2020/019104 patent/WO2020172457A1/fr not_active Ceased
- 2020-02-20 MX MX2021009722A patent/MX2021009722A/es unknown
- 2020-02-20 PE PE2021001367A patent/PE20211979A1/es unknown
- 2020-02-20 SG SG11202108734VA patent/SG11202108734VA/en unknown
- 2020-02-20 AR ARP200100461A patent/AR118144A1/es unknown
- 2020-02-20 TW TW109105560A patent/TWI879756B/zh active
- 2020-02-20 PH PH1/2021/552002A patent/PH12021552002A1/en unknown
- 2020-02-20 EP EP20711737.5A patent/EP3927743A1/fr active Pending
- 2020-02-20 CN CN202080015804.2A patent/CN113614110B/zh active Active
- 2020-02-20 EA EA202192294A patent/EA202192294A1/ru unknown
- 2020-02-20 KR KR1020217028927A patent/KR20210135518A/ko not_active Ceased
- 2020-02-20 BR BR112021015656-9A patent/BR112021015656A2/pt unknown
-
2021
- 2021-08-16 US US17/402,986 patent/US12240902B2/en active Active
- 2021-08-16 IL IL285651A patent/IL285651A/en unknown
- 2021-08-16 US US17/403,406 patent/US20220073609A1/en not_active Abandoned
- 2021-08-18 CL CL2021002206A patent/CL2021002206A1/es unknown
- 2021-09-17 CO CONC2021/0012230A patent/CO2021012230A2/es unknown
- 2021-09-17 EC ECSENADI202169105A patent/ECSP21069105A/es unknown
-
2024
- 2024-08-21 JP JP2024139367A patent/JP7842822B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113614110A (zh) | 2021-11-05 |
| SG11202108734VA (en) | 2021-09-29 |
| EP3927743A1 (fr) | 2021-12-29 |
| PE20211979A1 (es) | 2021-10-05 |
| US20220073609A1 (en) | 2022-03-10 |
| JP2024164116A (ja) | 2024-11-26 |
| TWI879756B (zh) | 2025-04-11 |
| BR112021015656A2 (pt) | 2021-10-05 |
| CL2021002206A1 (es) | 2022-04-22 |
| CO2021012230A2 (es) | 2021-09-30 |
| WO2020172457A1 (fr) | 2020-08-27 |
| CN113614110B (zh) | 2025-03-25 |
| PH12021552002A1 (en) | 2022-09-19 |
| WO2020172450A1 (fr) | 2020-08-27 |
| TW202045543A (zh) | 2020-12-16 |
| AU2020226754A1 (en) | 2021-09-16 |
| JP7543290B2 (ja) | 2024-09-02 |
| IL285651A (en) | 2021-09-30 |
| CA3130086A1 (fr) | 2020-08-27 |
| JP2022520868A (ja) | 2022-04-01 |
| EA202192294A1 (ru) | 2021-12-24 |
| US12240902B2 (en) | 2025-03-04 |
| ECSP21069105A (es) | 2021-11-18 |
| MX2021009722A (es) | 2021-09-14 |
| JP7842822B2 (ja) | 2026-04-08 |
| KR20210135518A (ko) | 2021-11-15 |
| AR118144A1 (es) | 2021-09-22 |
| US20220119522A1 (en) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
| MA56074A (fr) | Anticorps contre le sars-cov-2 et leurs procédés d'utilisation | |
| MA52390A (fr) | Anticorps anti-coronavirus et procédés d'utilisation | |
| EP3953385A4 (fr) | Anticorps cd19 et leurs procédés d'utilisation | |
| EP3826641A4 (fr) | Compositions d'anticorps anti-fcrn et leurs procédés d'utilisation | |
| EP3797123A4 (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
| EP3917564A4 (fr) | Anticorps anti-claudine 18 et leurs méthodes d'utilisation | |
| MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
| EP3731867A4 (fr) | Anticorps anti-lrp5/6 et leurs procédés d'utilisation | |
| EP3852805A4 (fr) | Anticorps anti-lilrb2 et leurs méthodes d'utilisation | |
| MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
| EP3472200A4 (fr) | Anticorps anti-myostatine et leurs procédés d'utilisation | |
| MA53328A (fr) | Anticorps anti-siglec-5 et leurs procédés d'utilisation | |
| EP3436476A4 (fr) | Anticorps anti-ryk et leurs procédés d'utilisation | |
| EP3938400A4 (fr) | Anticorps cd22 et leurs procédés d'utilisation | |
| EP3867271A4 (fr) | Formulations d'anticorps anti-rsv et leurs procédés d'utilisation | |
| EP3873939A4 (fr) | Anticorps anti-cd79b et récepteurs d'antigènes chimériques et leurs procédés d'utilisation | |
| EP3710589A4 (fr) | Anticorps anti-c1s et procédés d'utilisation | |
| MA51837A (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
| EP3966248A4 (fr) | Anticorps humanisés dirigés contre la mucine-16 et leurs procédés d'utilisation | |
| MA51207A (fr) | Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation | |
| EP3873941A4 (fr) | Anticorps anti-pd-1 humain et procédés d'utilisation associés | |
| EP3880714A4 (fr) | Anticorps dirigés contre la mucine-16 et leurs procédés d'utilisation |